Kemnay Advisory Services’s Sarepta Therapeutics SRPT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$17.4K Buy
+954
New +$17.8K ﹤0.01% 587
2021
Q1
– Sell
-5,681
Closed -$969K – 108
2020
Q4
$969K Buy
+5,681
New +$842K 0.12% 47
2020
Q3
– Sell
-3,649
Closed -$585K – 99
2020
Q2
$585K Sell
3,649
-4,684
-56% -$637K 0.09% 48
2020
Q1
$815K Sell
8,333
-12,576
-60% -$1.44M 0.23% 35
2019
Q4
$2.7M Buy
+20,909
New +$2.11M 0.67% 19

Other funds holding SRPT

Kemnay Advisory Services's SRPT Position: Q3 2026 in Review

Kemnay Advisory Services opened a new position in Sarepta Therapeutics (SRPT) in Q3 2026: 954 shares worth $17.4K. The stake represents ﹤0.01% of the portfolio and ranks #587 among its holdings. This is a return to the name: Kemnay Advisory Services previously reported a position in SRPT as recently as Q4 2020.

Kemnay Advisory Services first reported a position in SRPT in Q4 2019 and has held it in 5 quarters since. The position peaked at $2.7M in Q4 2019. 303 funds tracked by Wall St. Rank hold SRPT as of Q3 2026.

  • Kemnay Advisory Services held 954 shares of Sarepta Therapeutics worth $17.4K as of Q3 2026.
  • Sarepta Therapeutics was a new Kemnay Advisory Services position in Q3 2026.
  • Sarepta Therapeutics made up ﹤0.01% of Kemnay Advisory Services's portfolio in Q3 2026, its #587 holding.
  • Kemnay Advisory Services first reported a position in Sarepta Therapeutics in Q4 2019 and has held it in 5 quarters since.
  • Kemnay Advisory Services's Sarepta Therapeutics position peaked at $2.7M in Q4 2019.
  • 303 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q3 2026.

Based on Kemnay Advisory Services's 13F filing for Q3 2026, filed 16 Nov 2026.